Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 10/20 | 0.47 |
| ▸ | GABRD | O14764 | 10/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 10/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 10/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 10/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 10/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 10/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 10/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 10/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 10/20 | 0.47 |
| ▸ | GABRE | P78334 | 10/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 10/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 10/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 10/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 10/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208876 | 0.85 | MAOB (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL206945 | 0.78 | ADCY1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL206491 | 0.78 | GABRP (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL206928 | 0.72 | CYP1A2 (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL207427 | 0.72 | MAOA (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2873532 | 0.69 | — | — | |
| SCHEMBL1094182 | 0.69 | MAOA (0.59) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL207069 | 0.68 | CYP1A2 (0.38) | MEN1KMT2AMAOBKDM4E | |
| Ammonia Solution, Strong SCHEMBL6962476 | 0.67 | — | — | |
| SCHEMBL208305 | 0.67 | TNKS (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-8058440-B2 | Process for producing 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-15 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110054177-A1 | PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-7880005-B2 | reacting 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine with an alkali metal nitrite in the presence of a reducing agent in an aqueous solution of an acidic compound; hydrolysis; industrial scale | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2266992-A2 | Process for producing thiazole derivative | Daiichi Sankyo Company, Limited (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1683800-A1 | PROCESS FOR PRODUCING THIAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-07-26 | — | — | EP | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054177-A1 | PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID | PAH, CA4, TET2 | GABRP 2565/4885GABRD 3731/4885GABRA1 2891/4885 |
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | GABRP 3231/4885GABRD 1519/4885GABRA1 2126/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | GABRP 1793/4885GABRD 284/4885GABRA1 1201/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | GABRP 2862/4885GABRD 593/4885GABRA1 1632/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | GABRP 2862/4885GABRD 593/4885GABRA1 1632/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | GABRP 2862/4885GABRD 593/4885GABRA1 1632/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | GABRP 2554/4885GABRD 1787/4885GABRA1 2320/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | GABRP 3087/4885GABRD 671/4885GABRA1 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.